Home
BCAX
BCAX News

Latest BICARA THERAPEUTICS INC (BCAX) News on April 2, 2025

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire

6 days ago

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

GlobeNewswire

8 days ago

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025

Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth

Simply Wall St.

21 days ago

Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

GlobeNewswire

a month ago

Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

GlobeNewswire

2 months ago

Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

MT Newswires

2 months ago

Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

GlobeNewswire

2 months ago

Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium

Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia

Clinical Trials Arena

3 months ago

Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia

MT Newswires

5 months ago

Bicara Therapeutics' Q3 Loss Narrows

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

5 months ago

Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

GlobeNewswire

5 months ago

Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference

Opening Day: Another trio of biotech IPOs make Friday debut

TipRanks

6 months ago

Opening Day: Another trio of biotech IPOs make Friday debut

Investing.com

6 months ago

MBX Biosciences earns Buy rating at three investment firms

GuruFocus.com

6 months ago

RA Capital Management's Strategic Acquisition of Bicara Therapeutics Shares

TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc

GuruFocus.com

6 months ago

TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc

FMR LLC Acquires New Stake in Bicara Therapeutics Inc

GuruFocus.com

6 months ago

FMR LLC Acquires New Stake in Bicara Therapeutics Inc

MT Newswires

6 months ago

Bicara Therapeutics Insider Bought Shares Worth $1,260,000, According to a Recent SEC Filing

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity

Pharmaceutical Technology

7 months ago

Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity

MT Newswires

7 months ago

MBX Biosciences Closes Upsized IPO

MT Newswires

7 months ago

Bicara Therapeutics Closes $362 Million IPO

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire

7 months ago

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Share on Social Networks: